Idiopathic pulmonary arterial hypertension in childhood

Cardiology in Review

Volumn 18, Issue 2, 2010, Pages 64-66

  Haworth, Sheila G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Endothelin receptor antagonists; Idiopathic pulmonary arterial hypertension; Phosphodiesterase inhibitors; Prostacyclin; Pulmonary vascular disease; Quality of life

Indexed keywords

ADRENOMEDULLIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; ELASTASE INHIBITOR; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL STIMULATING AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RHO KINASE INHIBITOR; SILDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANAMNESIS; ARTERIAL OXYGEN SATURATION; CHILDHOOD DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; GENE THERAPY; HEART CATHETERIZATION; HUMAN; IDIOPATHIC DISEASE; LUNG BIOPSY; LUNG FUNCTION TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THORAX RADIOGRAPHY; THYROID FUNCTION TEST; TREATMENT OUTCOME;

AGE FACTORS; ANIMALS; CHILD; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; PROSTAGLANDINS I; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77149147118     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181ce03df     Document Type: Review

References (22)

1. Higgenbottam TW, Wells F, Wheeldon D, et al. Treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet. 1984;1:1046-1047.
2. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197-1208.
3. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
4. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart. 2006;92:664-670.
5. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:697-704.
6. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
7. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
8. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart. 2009;95:312-317.
9. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation. 2004;110:660-665.
10. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004;43:33S-39S.
11. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105:1672-1678.
12. Du L, Sullivan CC, Chu D, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 2003;348:500-509.
13. Yeager ME, Golpon HA, Voelkel NF, et al. Microsatellite mutational analysis of endothelial cells within plexiform lesions from patients with familial, pediatric, and sporadic pulmonary hypertension. Chest. 2002;121:61S.
14. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98:209-217.
15. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115:2811-2821.
16. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-1413.
17. Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113:2630-2641.
18. Yu Y, Fantozzi I, Remillard CV, et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004;101:13861-13866.
19. Lammers AE, Hislop AA, Flynn Y, et al. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child. 2008;93:464-468.
20. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40S-47S.
21. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-1482.
22. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.